Amazon is one of the world's largest companies. Here's a look at its recent performance.I won't sugarcoat it: Amazon (AMZN 0.23%) hasn't exactly been the best-performing stock over the past five years, with a gain of about 56% during that time period. In other words, a $1,000 investment in Amazon five years ago -- on Sept. 17, 2020 -- would be worth $1,560 today.That is significantly less than the S&P 500 (^GSPC 0.49%), which has delivered a 112% total return over the past five years. So, why did Amazon pro ...

公司股价表现 - 周五MRNA股价下跌7% 因华盛顿邮报报道称有卫生官员通过疫苗不良事件报告系统将25名儿童死亡与新冠疫苗相关联[2] - 该股年初至今跌幅接近45% 过去一个月下跌12.6% 过去一年累计下跌66.3%[2][5][8] 业务概况 - 公司专注于开发基于mRNA的治疗方法和疫苗 覆盖传染病、免疫肿瘤学、罕见病、心血管和自身免疫疾病领域[4] - 目前拥有44个研发项目 其中26个临床试验涵盖七种治疗模式[4] 财务表现比较 - 最近十二个月收入增长率为-38.8% 表现逊于同行PFE、ALNY、SRPT、ABBV和AMGN[8] - 营业利润率为-107.1% 在同行中处于最低水平 而PFE的营业利润率为26.1%[8] - 市盈率为-3.1 处于亏损状态 表现不及PFE、ALNY、ABBV和AMGN[8] 同业比较分析 - 通过与同行在规模、估值、增长和利润率方面的比较 有助于评估公司是否真正落后以及该趋势是否可能持续[3][5] - Trefis高质量投资组合采用30只股票组合 历史上持续跑赢标普500、标普中盘和罗素2000指数基准[9]